112 related articles for article (PubMed ID: 9698467)
1. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
Husain A; Rosales N; Schwartz GK; Spriggs DR
Gynecol Oncol; 1998 Jul; 70(1):17-22. PubMed ID: 9698467
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
3. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Husain A; Yan XJ; Rosales N; Aghajanian C; Schwartz GK; Spriggs DR
Clin Cancer Res; 1997 Nov; 3(11):2089-97. PubMed ID: 9815601
[TBL] [Abstract][Full Text] [Related]
4. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan S; Smith ML; Rivet DJ; Duba D; Zhan Q; Kohn KW; Fornace AJ; O'Connor PM
Cancer Res; 1995 Apr; 55(8):1649-54. PubMed ID: 7712469
[TBL] [Abstract][Full Text] [Related]
5. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
8. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
Qamar L; Davis R; Anwar A; Behbakht K
Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
11. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
12. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
[TBL] [Abstract][Full Text] [Related]
13. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
Futagami M; Sato S; Sakamoto T; Yokoyama Y; Saito Y
Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153
[TBL] [Abstract][Full Text] [Related]
14. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
15. p53 gene status and chemosensitivity in ovarian cancer.
Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
[TBL] [Abstract][Full Text] [Related]
16. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
17. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
18. p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2004 Aug; 12(2):357-61. PubMed ID: 15254702
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and p53-dependent apoptosis in ovarian cancer cells.
Akeshima R; Kigawa J; Takahashi M; Oishi T; Kanamori Y; Itamochi H; Shimada M; Kamazawa S; Sato S; Terakawa N
Br J Cancer; 2001 Jun; 84(11):1551-5. PubMed ID: 11384107
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
